Neogenomics INC 10-Q quarterly reports

NeoGenomics, Inc. announced its financial results for the second quarter ended June 30, 2026, showing an 11.2% increase in revenue and a return to net income.

NeoGenomics reports an 11.1% revenue increase to $186.7 million for Q1 2026, driven by higher test volumes and strategic initiatives.

NeoGenomics reported an 11.9% revenue increase in Q3 2025, reaching $187.8 million, but saw its net loss widen to $27.1 million due to significant impairment charges and higher operating costs.

NeoGenomics, Inc. reported a 10.2% increase in Q2 2025 revenue to $181.3 million, driven by test volume and strategic reimbursement initiatives, but saw its net loss widen significantly to $45.1 million due to substantial impairment charges from the planned sale of Trapelo Health and the wind-down of InVisionFirst-Lung.

NeoGenomics reports a 7.5% increase in revenue for Q1 2025, driven by higher test volume and average unit price, while completing its restructuring program.

NeoGenomics' Q3 2024 results show a revenue increase driven by Clinical Services, while Advanced Diagnostics experienced a slight decline.

NeoGenomics' second quarter 2024 results show a significant increase in Clinical Services revenue, while Advanced Diagnostics revenue experienced a slight decrease.

NeoGenomics' first quarter 2024 results show a significant increase in revenue driven by the Clinical Services segment, despite a slight decrease in Advanced Diagnostics revenue.